Trial Profile
Clinical trial of parathyroid hormone and alendronate [alendronic acid] in combination in the treatment of osteoporosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Alendronic acid (Primary) ; Parathyroid hormone (Primary)
- Indications Postmenopausal osteoporosis
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
- Acronyms PaTH
- 21 Oct 2020 According to an Ascendis Pharma media release, data from this trial will be presented at European Calcified Tissue Society (ECTS) 2020.
- 10 Sep 2020 According to an Ascendis Pharma media release Dr. Khan is the primary investigator .
- 10 Sep 2020 According to an Ascendis Pharma media release, results from the 4-week, fixed dose double-blinded portion of this trial will be presented at American Society for Bone and Mineral Research (ASBMR) 2020 Annual Meeting Virtual Event.